癌癥研究中的轉化代謝組學
在過去的十年中，在引進新的驗證癌癥代謝生物標志物的臨床實踐上有一個瓶頸。不幸的是，早期發現的癌癥并沒有足夠靈敏的生物標志物，并且監測治療的癌癥抗原仍然存在。新診斷學的需要導致了非靶向代謝組學對特定癌癥的早期生物標志物的發現的探索以及靶向代謝組學用于研究腫瘤的發生發展機理。成功的轉化策略將允許癌癥治療地早期干預，以提高生存率。我們的方法是用來實現這些目標的，以實現轉化代謝組學在癌癥方面取得進展。
這篇文章中使用的代謝組學技術譜領生物已開發成熟、完善，并對外提供服務，已為多位客戶提供服務并獲得好評。
文獻內容
Title:Translational metabolomics in cancer research.
Author：Nathaniel W Snyder,Clementina Mesaros & Ian A Blair
Journal: Biomark Med
Keywords: cancer、cancer diagnosis、diagnostic biomarkers、lipidomics、liquid chromatogr-aphy-mass spectrometry、NMR spectroscopy、prognostic biomarkers、untargeted metabolon-mics targeted metabolomics.
Abstract：
Over the last decade there has been a bottleneck in the introduction of new validated cancer metabolic biomarkers in o clinical practice. Unfortunately, there are no biomarkers with adequate sensitivity for the early detection of cancer, and there remain a reliance on cancer antigens for monitoring treatment. The need for new diagnostics has led to the exploration of untargeted metabolomics for discovery of early biomarkers of specific cancers and targeted metabolomics to elucidate mechanistic aspects of tumor progression. The successful translation of such strategies to the treatment of cancer would allow earlier intervention to improve survival. We have reviewed the methodology that is being used to achieve these goals together with recent advances in implementing translational metabolomics in cancer.
